Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
Peters
G J
GJ
van Groeningen
C J
CJ
Giaccone
G
G
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics*; D002626:Chemistry, Pharmaceutical; D050744:Dihydrouracil Dehydrogenase (NAD+); D004338:Drug Combinations; D005472:Fluorouracil / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D044925:Oxidoreductases Acting on CH-CH Group Donors; D010094:Oxonic Acid / Q000493:pharmacokinetics; D011355:Prodrugs / Q000494:pharmacology; D011725:Pyridines / Q000493:pharmacokinetics; D005641:Tegafur / Q000493:pharmacokinetics
C417063:5-chlorodihydroxypyridine; D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011355:Prodrugs; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; D050744:Dihydrouracil Dehydrogenase (NAD+); D005472:Fluorouracil